NL6605692A - - Google Patents
Info
- Publication number
- NL6605692A NL6605692A NL6605692A NL6605692A NL6605692A NL 6605692 A NL6605692 A NL 6605692A NL 6605692 A NL6605692 A NL 6605692A NL 6605692 A NL6605692 A NL 6605692A NL 6605692 A NL6605692 A NL 6605692A
- Authority
- NL
- Netherlands
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE571165 | 1965-04-30 | ||
| US55822666A | 1966-06-17 | 1966-06-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL6605692A true NL6605692A (US06566495-20030520-M00011.png) | 1966-10-31 |
| NL143550B NL143550B (nl) | 1974-10-15 |
Family
ID=26654650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL666605692A NL143550B (nl) | 1965-04-30 | 1966-04-28 | Werkwijze voor de bereiding van een geneesmiddel met blokkeringseffect ten opzichte van hartstimulantia, dat als actieve verbinding een 1-(gesubstitueerd fenoxy)-2-hydroxy-3-isopropylaminopropaan en/of een zout daarvan bevat, en werkwijze voor de bereiding van de actieve verbinding. |
Country Status (11)
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| WO2007024945A1 (en) | 2005-08-25 | 2007-03-01 | Novartis Ag | Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase |
| WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
| WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3969512A (en) * | 1935-11-15 | 1976-07-13 | Boehringer Ingelheim Gmbh | N,N'bis-(3-phenoxy-2-hydroxy-propyl)-alkylenediamines and salts thereof |
| SE354851B (US06566495-20030520-M00011.png) * | 1970-02-18 | 1973-03-26 | Haessle Ab | |
| US3959486A (en) * | 1970-05-27 | 1976-05-25 | Imperial Chemical Industries Limited | Method for producing β-adrenergic blockage with alkanolamine derivatives |
| US4059622A (en) * | 1970-05-27 | 1977-11-22 | Imperial Chemical Industries Limited | Alkanolamine derivatives |
| SE386892B (sv) * | 1972-07-06 | 1976-08-23 | Haessle Ab | Forfarande for framstellning av oxaminoforeningar |
| US4018825A (en) * | 1972-07-27 | 1977-04-19 | Warner-Lambert Company | 5-Hydroxy-α-(substituted aminomethyl)-m-xylene-α,α'-diols |
| US4067904A (en) * | 1975-12-19 | 1978-01-10 | Mead Johnson & Company | Alkylsulfonylphenoxypropanolamine derivatives |
| US4119729A (en) * | 1975-12-19 | 1978-10-10 | Mead Johnson & Company | Alkylsulfonylphenoxypropanolamine therapeutic process |
| US4243681A (en) * | 1977-10-11 | 1981-01-06 | Mead Johnson & Company | Alkylthiophenoxypropanolamines and pharmaceutical compositions and uses thereof |
| DE2963311D1 (en) * | 1978-12-29 | 1982-08-26 | Ciba Geigy Ag | Propenyl-substituted phenolglycidyl ethers, process for their preparation and their use |
| US4945182A (en) * | 1985-12-24 | 1990-07-31 | Merck & Co., Inc. | Oculoselective beta-blockers |
| US5254595A (en) * | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| JP2780559B2 (ja) * | 1991-01-25 | 1998-07-30 | 信越化学工業株式会社 | アリル基又はプロペニル基を持つナフタレン誘導体 |
| CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| DK0759299T3 (da) * | 1995-08-16 | 2000-08-07 | Lilly Co Eli | Potensering af serotoninrespons |
| US7034059B2 (en) * | 2001-07-02 | 2006-04-25 | Sepracor Inc. | Methods of using norfluoxetine |
| US20030087963A1 (en) | 2001-09-13 | 2003-05-08 | Senanayake Chris H. | Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites |
| US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
| EP2050441A1 (en) | 2007-10-19 | 2009-04-22 | Université Victor Segalen Bordeaux 2 | Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
| US8987262B2 (en) | 2007-10-19 | 2015-03-24 | Universite de Bordeaux | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
| EP2959904A1 (en) | 2014-06-27 | 2015-12-30 | Institut De Recerca Contra La Leucemia Josep Carreras | Methods for treating, diagnosing and prognosing a haematological malignancy |
| FR3030514A1 (fr) * | 2014-12-18 | 2016-06-24 | Centre De Coop Int En Rech Agronomique Pour Le Dev (Cirad) | Dimeres polyaromatiques |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2967201A (en) * | 1958-06-02 | 1961-01-03 | Lilly Co Eli | Alkylaminoalkyl ethers of phenols |
| NL300886A (US06566495-20030520-M00011.png) * | 1962-11-23 | |||
| NL301580A (US06566495-20030520-M00011.png) * | 1962-12-11 | |||
| GB1069345A (en) * | 1963-07-19 | 1967-05-17 | Ici Ltd | New alkanolamine derivatives |
| NL131194C (US06566495-20030520-M00011.png) * | 1963-07-19 | |||
| DE1493454C3 (de) * | 1963-08-26 | 1980-04-30 | C.H. Boehringer Sohn, 6507 Ingelheim | 1 -Aryloxy^-hydroxy-S-isopropylaminopropane und deren Salze sowie deren Herstellung und darauf basierende Arzneimittel |
| CH455834A (de) * | 1964-10-14 | 1968-05-15 | Ciba Geigy | Verfahren zur Herstellung des neuen 1-Isopropylamino-2-hydroxy-3-(2'-isopropoxy-phenoxy)-propans oder seinen Salzen |
-
1966
- 1966-01-18 US US521436A patent/US3466325A/en not_active Expired - Lifetime
- 1966-01-26 GB GB40546/68A patent/GB1140860A/en not_active Expired
- 1966-01-26 GB GB3531/66A patent/GB1140508A/en not_active Expired
- 1966-01-28 JP JP41004651A patent/JPS50653B1/ja active Pending
- 1966-01-29 DE DEA51453A patent/DE1294955B/de active Pending
- 1966-03-22 BE BE678208D patent/BE678208A/xx not_active IP Right Cessation
- 1966-03-31 CH CH469666A patent/CH484053A/de not_active IP Right Cessation
- 1966-04-05 NO NO162482A patent/NO115797B/no unknown
- 1966-04-26 FI FI1089/66A patent/FI42955B/fi active
- 1966-04-26 BR BR178981/66A patent/BR6678981D0/pt unknown
- 1966-04-27 FR FR59328A patent/FR5745M/fr not_active Expired
- 1966-04-28 NL NL666605692A patent/NL143550B/xx not_active IP Right Cessation
- 1966-06-17 US US558226A patent/US3466376A/en not_active Expired - Lifetime
-
1969
- 1969-08-15 US US872789*A patent/US3631108A/en not_active Expired - Lifetime
-
1970
- 1970-04-03 FI FI0931/70A patent/FI44392B/fi active
- 1970-12-28 JP JP45120574A patent/JPS4929182B1/ja active Pending
-
1972
- 1972-12-14 JP JP47124826A patent/JPS4930819B1/ja active Pending
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017964A1 (en) | 2002-08-19 | 2004-03-04 | Pfizer Products Inc. | Combination therapy for hyperproliferative diseases |
| WO2007024945A1 (en) | 2005-08-25 | 2007-03-01 | Novartis Ag | Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase |
| EP2256118A1 (en) | 2005-08-25 | 2010-12-01 | Novartis AG | Condensed imidazolo derivatives for the inhibition of aromatase |
| EP2270011A1 (en) | 2005-08-25 | 2011-01-05 | Novartis AG | Condensed imidazolo derivatives for the inhibition of aromatase |
| EP2392567A1 (en) | 2005-10-21 | 2011-12-07 | Bristol-Myers Squibb Company | Benzothiazine derivatives and their use as lxr modulators |
| WO2007062314A2 (en) | 2005-11-23 | 2007-05-31 | Bristol-Myers Squibb Company | Heterocyclic cetp inhibitors |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2923706A1 (en) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia |
| WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| US3466325A (en) | 1969-09-09 |
| DE1294955B (de) | 1969-05-14 |
| JPS4930819B1 (US06566495-20030520-M00011.png) | 1974-08-16 |
| FR5745M (US06566495-20030520-M00011.png) | 1968-01-29 |
| BR6678981D0 (pt) | 1973-09-18 |
| US3631108A (en) | 1971-12-28 |
| CH484053A (de) | 1970-01-15 |
| GB1140860A (en) | 1969-01-22 |
| NL143550B (nl) | 1974-10-15 |
| BE678208A (US06566495-20030520-M00011.png) | 1966-09-01 |
| FI42955B (US06566495-20030520-M00011.png) | 1970-09-02 |
| US3466376A (en) | 1969-09-09 |
| GB1140508A (en) | 1969-01-22 |
| NO115797B (US06566495-20030520-M00011.png) | 1968-12-09 |
| JPS50653B1 (US06566495-20030520-M00011.png) | 1975-01-10 |
| FI44392B (US06566495-20030520-M00011.png) | 1971-08-02 |
| JPS4929182B1 (US06566495-20030520-M00011.png) | 1974-08-01 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NL80 | Information provided on patent owner name for an already discontinued patent |
Owner name: HASSLE |
|
| V4 | Discontinued because of reaching the maximum lifetime of a patent |